fenofibrate has been researched along with Choroid Neovascularization in 4 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fenofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist and has been shown to have therapeutic effects on diabetic retinopathy (DR)." | 7.91 | Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration. ( Chen, Q; Deng, G; Du, Y; Ma, JX; Ma, X; Matlock, G; Meng, T; Qiu, F; Shao, Y; Wang, X; Wu, W; Xu, Q; Zhou, K, 2019) |
| "Fenofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist and has been shown to have therapeutic effects on diabetic retinopathy (DR)." | 3.91 | Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration. ( Chen, Q; Deng, G; Du, Y; Ma, JX; Ma, X; Matlock, G; Meng, T; Qiu, F; Shao, Y; Wang, X; Wu, W; Xu, Q; Zhou, K, 2019) |
| "Fenofibrate could inhibit CNV formation." | 1.48 | Impact of fenofibrate on choroidal neovascularization formation and VEGF-C plus VEGFR-3 in Brown Norway rats. ( Chen, QB; Geng, Y; Guan, M; Hua, HR; Li, Y; Xi, XT; Yang, JH; Zhao, JF, 2018) |
| "Fenofibrate treatment in type 2 diabetes patients reduces progression of diabetic retinopathy independent of its peroxisome proliferator-activated receptor (PPAR)α agonist lipid lowering effect." | 1.43 | Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. ( Burnim, SB; Edin, ML; Fu, Z; Gong, Y; Hellström, A; Liegl, RG; Lih, FB; Liu, CH; Meng, SS; SanGiovanni, JP; Shao, Z; Smith, LEH; Sun, Y; Wang, Z; Zeldin, DC, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qiu, F | 2 |
| Matlock, G | 2 |
| Chen, Q | 2 |
| Zhou, K | 2 |
| Du, Y | 2 |
| Wang, X | 2 |
| Ma, JX | 2 |
| Zhao, JF | 1 |
| Hua, HR | 1 |
| Chen, QB | 1 |
| Guan, M | 1 |
| Yang, JH | 1 |
| Xi, XT | 1 |
| Li, Y | 1 |
| Geng, Y | 1 |
| Meng, T | 1 |
| Shao, Y | 1 |
| Ma, X | 1 |
| Wu, W | 1 |
| Deng, G | 1 |
| Xu, Q | 1 |
| Gong, Y | 1 |
| Shao, Z | 1 |
| Fu, Z | 1 |
| Edin, ML | 1 |
| Sun, Y | 1 |
| Liegl, RG | 1 |
| Wang, Z | 1 |
| Liu, CH | 1 |
| Burnim, SB | 1 |
| Meng, SS | 1 |
| Lih, FB | 1 |
| SanGiovanni, JP | 1 |
| Zeldin, DC | 1 |
| Hellström, A | 1 |
| Smith, LEH | 1 |
4 other studies available for fenofibrate and Choroid Neovascularization
| Article | Year |
|---|---|
Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration.
Topics: Animals; Blotting, Western; Capillary Permeability; Choroidal Neovascularization; Disease Models, An | 2017 |
Impact of fenofibrate on choroidal neovascularization formation and VEGF-C plus VEGFR-3 in Brown Norway rats.
Topics: Analysis of Variance; Animals; Choroid; Choroidal Neovascularization; Disease Models, Animal; Fenofi | 2018 |
Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Topics: Animals; Capillary Permeability; Choroidal Neovascularization; Diabetes Mellitus, Experimental; Diab | 2019 |
Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Choroidal Neovascularization; Cytochrome P-450 Enzyme Inhibitors; | 2016 |